{
  "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
  "docSlug": "6d3545a6c010d7cb",
  "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
  "authorId": "GoldmanSachs",
  "authorName": "EyePoint Pharmaceuticals",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 23,
  "pageCount": 29,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "data_table",
  "function": "quantify_impact",
  "density": "dense",
  "nDataPoints": 36,
  "notes": "Supplement-free is defined as patients who did not receive a supplement at any point during the study.",
  "elementsJson": [
    "headline_text",
    "line_chart",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/23",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.16,
        "x": 0.815,
        "y": 0.205
      },
      "kind": "callout",
      "text": "Mean Change in BCVA vs Aflibercept: DURAVYU 2.7mg +7.3",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52eca4c5-7f63-4267-91a4-847a3381a127",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.16,
        "x": 0.815,
        "y": 0.545
      },
      "kind": "callout",
      "text": "Mean Change in BCVA vs Aflibercept: DURAVYU 2.7mg -73.7",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8a7ce6b-1b57-4a02-9bf4-e2d1a00b1946",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.11,
        "y": 0.235
      },
      "kind": "chart",
      "text": "MEAN CHANGE IN BCVA FROM BASELINE",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28ac6047-6a76-4dca-bd36-024421a3ca88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.11,
        "y": 0.55
      },
      "kind": "chart",
      "text": "MEAN CHANGE IN CST FROM BASELINE",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78a6ca88-16c7-4530-9f55-2cfe450c1eb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.3,
        "y": 0.9
      },
      "kind": "list",
      "text": "DURAVYU 2.7mg (n=7), DURAVYU 1.3mg (n=6), aflibercept 2mg (n=3)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3dbb8590-c42a-4c56-b464-31e03ec97d22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Mean Change in BCVA: +10.3",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-1d6c-779c-a620-2d0ebf8f5a78",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.2,
        "y": 0.89
      },
      "kind": "paragraph",
      "text": "Supplement-free is defined as patients who did not receive a supplement at any point during the study.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22f346a2-a3ca-4a45-9aad-16839502162a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Sub-Group of Supplement-Free Patients Demonstrated Eyes Treated with DURAVYU 2.7mg had Better Visual and Anatomical Outcomes",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b49d7fa-b3c6-4994-a8c0-24dc812d5399",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data-Ink Ratio",
      "slug": "data-ink-ratio",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "574c4284-db70-4018-8bff-7ded40130cb6",
      "evidence": "chart/line: MEAN CHANGE IN BCVA FROM BASELINE\nchart/line: MEAN CHANGE IN CST FROM BASELINE",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}